Nabi Biopharmaceuticals opens new facility
Nabi Biopharmaceuticals has opened its new vaccine manufacturing facility in Boca Raton, Florida, US.
Nabi Biopharmaceuticals has opened its new vaccine manufacturing facility in Boca Raton, Florida, US.
The scalable facility was completed in just eight months, and will be used to produce commercial quantities of StaphVAX [Staphylococcus aureus Polysaccharide Conjugate Vaccine], which iscurrently in Phase III development to prevent S. aureus infections in end-stage renal (kidney) disease (ESRD) patients.
Approximately 12,000 square feet, it will also be use to manufacture NicVAX [Nicotine Conjugate Vaccine], a vaccine to prevent and treat nicotine addiction; and next generation Gram-positive pipeline vaccine products.
The facility will be dedicated to the late Walter Karakawa PhD, a pioneer in immunology and biochemistry who discovered that S. aureus bacteria are covered by capsular polysaccharides (complex sugar molecules); a finding that was critical to understanding the make-up and typing of S. aureus and led to the genesis and later development of the StaphVAX vaccine. He died in 1993 at the age of 62.